RxDoctor Payments Data

Dalton Henderson, APRN

Family · Paducah, KYNPI 1841914439

Payments from drug & device makers

$6,017in general payments, 2019–2025

Across 361 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$888
  • Lilly USA, LLC$748
  • AstraZeneca$507
  • Pfizer$372
  • Bayer$280
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$6,017100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,017 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$67,378
Medicare patients
270
Services billed
6,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide136$148,653
OzempicSemaglutide41$53,289
JardianceEmpagliflozin31$44,899
RybelsusSemaglutide21$31,513
EliquisApixaban31$31,143
FarxigaDapagliflozin Propanediol17$17,446
VraylarCariprazine Hcl12$17,079
Repatha SureclickEvolocumab19$15,399
TrulancePlecanatide13$8,107
Novolog FlexpenInsulin Aspart27$5,064
Pantoprazole Sodium116$2,100
Aripiprazole18$2,005
SynthroidLevothyroxine Sodium15$1,522
Pregabalin34$1,210
Albuterol Sulfate HfaAlbuterol Sulfate68$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$748$148,653136 claims
Novo NordiskOzempic, Rybelsus$888$84,80262 claims
Boehringer IngelheimJardiance$274$44,89931 claims
PfizerEliquis$372$31,14331 claims
AbbVieVraylar, Synthroid$1,217$18,60127 claims
AstraZenecaFarxiga$507$17,44617 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$88$8,10713 claims
Almatica Pharma LLCSertraline Hcl$28$37045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →